Zura Bio (ZURA) | Financial Analysis & Statements
Zura Bio Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-18.4M
Net Income
-17.2M
Balance Sheet Metrics
Total Assets
113.9M
Total Liabilities
12.4M
Shareholders Equity
101.5M
Debt to Equity
0.12
Cash Flow Metrics
Operating Cash Flow
-14.6M
Free Cash Flow
-22.3M
Revenue & Profitability Trend
Zura Bio Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 42.1M | 24.4M | 44.0M | 23.7M |
| Selling, General & Administrative | 33.2M | 30.8M | 18.6M | 3.5M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 75.2M | 55.2M | 62.6M | 27.2M |
| Operating Income | -75.2M | -55.2M | -62.6M | -27.2M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | 6.3M | 8.0M | 2.2M | 8.0K |
| Interest Expense | - | - | - | - |
| Other Non-Operating Income | 260.0K | -5.2M | -111.0K | -179.0K |
| Pre-tax Income | -68.6M | -52.4M | -60.6M | -27.3M |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -68.6M | -52.4M | -60.6M | -27.3M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | ||||
| EBITDA | -75.2M | -49.9M | -64.8M | -27.2M |
| EPS (Basic) | $-1.06 | $-0.60 | $-2.09 | $-12.19 |
| EPS (Diluted) | $-1.06 | $-0.60 | $-2.09 | $-12.19 |
| Basic Shares Outstanding | 94160138 | 75070761 | 33064036 | 2111000 |
| Diluted Shares Outstanding | 94160138 | 75070761 | 33064036 | 2111000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Zura Bio Balance Sheet From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 109.4M | 176.5M | 99.8M | 1.6M | 4.7M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 2.9M | 2.2M | 1.0M | 209.0K | - |
| Total Current Assets | 112.3M | 178.7M | 100.8M | 1.8M | 4.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | - | - | - | - | - |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.5M | 698.0K | 0 | 145.0M | - |
| Total Non-Current Assets | 1.6M | 789.0K | 0 | 3.5M | 0 |
| Total Assets | 113.9M | 179.5M | 100.8M | 5.3M | 4.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.3M | 733.0K | 2.7M | 2.0M | - |
| Short-term Debt | - | - | - | 7.8M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 2.6M | - |
| Total Current Liabilities | 12.4M | 19.5M | 20.3M | 14.8M | 39.0K |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | - | - | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 990.0K | 12.5M | 12.5M |
| Total Liabilities | 12.4M | 19.5M | 21.3M | 27.3M | 12.5M |
| Equity | |||||
| Common Stock | 7.0K | 7.0K | 4.0K | 0 | 0 |
| Retained Earnings | -224.5M | -155.9M | -103.5M | -32.1M | -7.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 101.5M | 160.0M | 79.6M | -22.1M | -7.8M |
| Key Metrics | |||||
| Total Debt | 0 | 0 | 0 | 7.8M | 0 |
| Working Capital | 99.9M | 159.2M | 80.5M | -13.0M | 4.7M |
Balance Sheet Composition
Zura Bio Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -68.6M | -52.4M | -60.6M | -27.3M |
| Depreciation & Amortization | 49.0K | 9.0K | - | - |
| Stock-Based Compensation | 12.3M | 16.8M | 9.7M | 334.0K |
| Working Capital Changes | -814.0K | -698.0K | 0 | 288.3K |
| Operating Cash Flow | -57.1M | -36.3M | -19.4M | -4.5M |
| Investing Activities | ||||
| Capital Expenditures | -113.0K | -75.0K | - | - |
| Acquisitions | - | - | - | - |
| Investment Purchases | - | - | - | - |
| Investment Sales | - | - | - | - |
| Investing Cash Flow | -113.0K | -75.0K | - | - |
| Financing Activities | ||||
| Share Repurchases | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Debt Issuance | - | - | - | - |
| Debt Repayment | - | 0 | -10.0M | 0 |
| Financing Cash Flow | -2.3M | 59.8M | 95.2M | 14.8M |
| Free Cash Flow | -64.9M | -33.2M | -23.1M | -13.2M |
| Net Change in Cash | -59.5M | 23.4M | 75.8M | 10.3M |
Cash Flow Trend
Zura Bio Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
7.95
Forward P/E
-56.50
Price to Book
4.10
PEG Ratio
-56.50
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-52.49%
Return on Assets
-32.05%
Financial Health
Current Ratio
9.05
Debt to Equity
0.00
Beta
0.24
Per Share Data
EPS (TTM)
$-1.06
Book Value per Share
$1.38
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ZURA | 536.1M | 7.95 | 4.10 | -52.49% | 0.00% | 0.00 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adaptive | 2.1B | -35.44 | 9.99 | -27.82% | -21.48% | 93.49 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Agios | 1.5B | 3.82 | 1.26 | -30.20% | 88.26% | 3.37 |
Financial data is updated regularly. All figures are in the company's reporting currency.






